JP7623279B2 - 小分子ｃｄ－４７阻害剤の他の抗癌剤との組み合わせ - Google Patents

小分子ｃｄ－４７阻害剤の他の抗癌剤との組み合わせ Download PDF

Info

Publication number
JP7623279B2
JP7623279B2 JP2021524166A JP2021524166A JP7623279B2 JP 7623279 B2 JP7623279 B2 JP 7623279B2 JP 2021524166 A JP2021524166 A JP 2021524166A JP 2021524166 A JP2021524166 A JP 2021524166A JP 7623279 B2 JP7623279 B2 JP 7623279B2
Authority
JP
Japan
Prior art keywords
cancer
combination
sirpα
certain embodiments
carcinoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021524166A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020095256A5 (https=
JP2022507025A (ja
JP2022507025A5 (https=
Inventor
ラマチャンドラ，ムラリドハラ
ゴヴィンダン ナイ サシクマル，ポッタイール
チャンドラッパ ダギナカッテ，ギリシュ
アイサル バルクドゥル，キラン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aurigene Oncology Ltd
Original Assignee
Aurigene Discovery Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurigene Discovery Technologies Ltd filed Critical Aurigene Discovery Technologies Ltd
Publication of JP2022507025A publication Critical patent/JP2022507025A/ja
Publication of JPWO2020095256A5 publication Critical patent/JPWO2020095256A5/ja
Publication of JP2022507025A5 publication Critical patent/JP2022507025A5/ja
Priority to JP2025006295A priority Critical patent/JP2025063207A/ja
Application granted granted Critical
Publication of JP7623279B2 publication Critical patent/JP7623279B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021524166A 2018-11-08 2019-11-08 小分子ｃｄ－４７阻害剤の他の抗癌剤との組み合わせ Active JP7623279B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025006295A JP2025063207A (ja) 2018-11-08 2025-01-16 小分子ｃｄ－４７阻害剤の他の抗癌剤との組み合わせ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201841042108 2018-11-08
IN201841042108 2018-11-08
PCT/IB2019/059602 WO2020095256A1 (en) 2018-11-08 2019-11-08 Combination of small molecule cd-47 inhibitors with other anti-cancer agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025006295A Division JP2025063207A (ja) 2018-11-08 2025-01-16 小分子ｃｄ－４７阻害剤の他の抗癌剤との組み合わせ

Publications (4)

Publication Number Publication Date
JP2022507025A JP2022507025A (ja) 2022-01-18
JPWO2020095256A5 JPWO2020095256A5 (https=) 2022-11-11
JP2022507025A5 JP2022507025A5 (https=) 2022-11-11
JP7623279B2 true JP7623279B2 (ja) 2025-01-28

Family

ID=69159806

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021524166A Active JP7623279B2 (ja) 2018-11-08 2019-11-08 小分子ｃｄ－４７阻害剤の他の抗癌剤との組み合わせ
JP2025006295A Pending JP2025063207A (ja) 2018-11-08 2025-01-16 小分子ｃｄ－４７阻害剤の他の抗癌剤との組み合わせ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025006295A Pending JP2025063207A (ja) 2018-11-08 2025-01-16 小分子ｃｄ－４７阻害剤の他の抗癌剤との組み合わせ

Country Status (14)

Country Link
US (3) US11311517B2 (https=)
EP (1) EP3876931A1 (https=)
JP (2) JP7623279B2 (https=)
KR (1) KR20210088584A (https=)
CN (2) CN112930181B (https=)
AU (1) AU2019375193A1 (https=)
BR (1) BR112021008781A2 (https=)
CA (1) CA3118843A1 (https=)
EA (1) EA202190776A1 (https=)
IL (1) IL282972B2 (https=)
MX (2) MX2021005240A (https=)
PH (1) PH12021550832A1 (https=)
SG (1) SG11202104192TA (https=)
WO (1) WO2020095256A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3737401A4 (en) * 2018-01-12 2021-09-15 Aurigene Discovery Technologies Limited 1,2,4-OXADIAZOLE COMPOUNDS AS INHIBITORS OF THE CD47 SIGNAL PATH
EP4291238A4 (en) * 2021-02-10 2024-10-09 Great Novel Therapeutics Biotech & Medicals Corporation PHARMACEUTICAL COMBINATION AND METHOD FOR OVERCOMING IMMUNE SUPPRESSION OR STIMULATING AN IMMUNE RESPONSE AGAINST CANCER
CN113018415B (zh) * 2021-03-17 2022-07-01 遵义医科大学 一种药物组合及其应用
CN113750215B (zh) * 2021-09-24 2023-06-23 暨南大学 用于治疗肿瘤的联合药物
WO2025083628A1 (en) 2023-10-19 2025-04-24 Aurigene Oncology Limited Pharmaceutically acceptable salt of a cd47-sirp alpha pathway inhibitor
WO2025229631A2 (en) * 2024-05-03 2025-11-06 Aurigene Oncology Limited A CD47-SIRPα BLOCKING AGENT FOR THE TREATMENT OF CANCER
US20250339404A1 (en) 2024-05-03 2025-11-06 Aurigene Oncology Limited COMBINATION THERAPY USING A CD47-SIRP alpha BLOCKING AGENT AND AZACITIDINE
CN118453879B (zh) * 2024-05-23 2025-10-03 大连医科大学附属第二医院 恩杂鲁胺与铜离子载体联合在制备前列腺癌治疗药物中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016142833A1 (en) 2015-03-10 2016-09-15 Aurigene Discovery Technologies Limited 1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
WO2018047139A1 (en) 2016-09-12 2018-03-15 Aurigene Discovery Technologies Limited Compounds as modulators of tigit signalling pathway
WO2018073754A1 (en) 2016-10-20 2018-04-26 Aurigene Discovery Technologies Limited Dual inhibitors of vista and pd-1 pathways
WO2019138367A1 (en) 2018-01-12 2019-07-18 Aurigene Discovery Technologies Limited 1,2,4-oxadiazole compounds as inhibitors of cd47 signalling pathways

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2672828A1 (en) * 2006-12-13 2008-06-26 Schering Corporation Methods of treatment
HRP20221260T1 (hr) 2010-05-14 2023-03-03 The Board Of Trustees Of The Leland Stanford Junior University Humanizirana i kimerna monoklonska protutijela za cd47
HRP20181052T1 (hr) 2013-09-06 2018-09-07 Aurigene Discovery Technologies Limited Derivati 1,2,4-oksadiazola kao imunomodulatori
EP3267985A4 (en) 2015-03-10 2018-07-25 Aurigene Discovery Technologies Limited 3-substituted-1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
WO2016168246A1 (en) 2015-04-14 2016-10-20 The Procter & Gamble Company Solid conditioning composition
CN104804093A (zh) 2015-05-27 2015-07-29 江苏春申堂药业有限公司 一种针对cd47的单域抗体
NZ741324A (en) 2015-09-21 2021-09-24 Erasmus Univ Medical Center Anti-cd47 antibodies and methods of use
EP3243522A1 (en) 2016-05-10 2017-11-15 Université Pierre et Marie Curie (Paris 6) Agonist agents of cd47 inducing programmed cell death and their use in the treatments of diseases associated with defects in programmed cell death
DK3454879T3 (da) 2016-05-10 2022-03-14 Inst Nat Sante Rech Med Hidtil ukendte forbindelser og farmaceutisk anvendelse deraf i behandlingen af kræft
WO2019175799A2 (en) * 2018-03-14 2019-09-19 Aurigene Discovery Technologies Limited Method of modulating tigit and pd-1 signalling pathways using 1,2,4-oxadiazole compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016142833A1 (en) 2015-03-10 2016-09-15 Aurigene Discovery Technologies Limited 1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
WO2018047139A1 (en) 2016-09-12 2018-03-15 Aurigene Discovery Technologies Limited Compounds as modulators of tigit signalling pathway
WO2018073754A1 (en) 2016-10-20 2018-04-26 Aurigene Discovery Technologies Limited Dual inhibitors of vista and pd-1 pathways
WO2019138367A1 (en) 2018-01-12 2019-07-18 Aurigene Discovery Technologies Limited 1,2,4-oxadiazole compounds as inhibitors of cd47 signalling pathways

Also Published As

Publication number Publication date
CA3118843A1 (en) 2020-05-14
IL282972B1 (en) 2025-02-01
CN112930181B (zh) 2025-05-13
IL282972A (en) 2021-06-30
EP3876931A1 (en) 2021-09-15
CN112930181A (zh) 2021-06-08
AU2019375193A1 (en) 2021-05-13
JP2022507025A (ja) 2022-01-18
US20250177358A1 (en) 2025-06-05
EA202190776A1 (ru) 2021-09-20
US20220241248A1 (en) 2022-08-04
JP2025063207A (ja) 2025-04-15
KR20210088584A (ko) 2021-07-14
US20200147054A1 (en) 2020-05-14
US12268670B2 (en) 2025-04-08
IL282972B2 (en) 2025-06-01
BR112021008781A2 (pt) 2021-08-03
SG11202104192TA (en) 2021-05-28
MX2021005240A (es) 2021-06-18
US11311517B2 (en) 2022-04-26
MX2024006094A (es) 2024-05-30
WO2020095256A1 (en) 2020-05-14
PH12021550832A1 (en) 2021-10-04
CN120305258A (zh) 2025-07-15

Similar Documents

Publication Publication Date Title
JP7623279B2 (ja) 小分子ｃｄ－４７阻害剤の他の抗癌剤との組み合わせ
JP7698699B2 (ja) Ｃｄ４７シグナル伝達経路の阻害剤としての１，２，４－オキサジアゾール化合物
JP7032583B2 (ja) アルギナーゼ活性を阻害する組成物及び方法
US20190099413A1 (en) Drug for cancer therapy characterized in that axl inhibitor and immune checkpoint inhibitor are administered in combination
TW201420117A (zh) 抗體－藥物複合體
KR20190067235A (ko) Vista 및 pd-1 경로의 이중 억제제
JP2018520352A (ja) アルギナーゼ活性を阻害するための組成物および方法
US20230404986A1 (en) Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1 and/or pd-l1 inhibitor
WO2018047143A1 (en) Vista signaling pathway inhibitory compounds useful as immunomodulators
KR20180059544A (ko) 글루타미나제 억제제와 면역-종양학적 약제에 의한 병용 요법
JP7417804B2 (ja) １，２，４－オキサジアゾール化合物を用いてｔｉｇｉｔおよびｐｄ－１のシグナル伝達経路をモジュレートする方法
TW201110981A (en) Combination therapy of an afucosylated CD20 antibody with fludarabine and/or mitoxantrone
KR20260018046A (ko) 이전의 면역 관문 억제제 노출 이력이 있는 대상체의 암 치료 방법
TW202434300A (zh) 藥物綴合物及其製備與使用方法
CN121218988A (zh) 治疗未接受bcl2抑制剂的受试者的癌症的方法
TWI832069B (zh) 用於預防或治療癌症且含有萘醌系化合物及免疫檢查點抑制劑作為活性成分的藥學組成物
EA045738B1 (ru) Комбинация маломолекулярных ингибиторов cd-47 с другими противораковыми агентами
TW202506190A (zh) 利用抗ｍｕｃ１抗體－藥物結合物投予的藥劑低敏感性癌之治療方法
CN121969366A (zh) 治疗与白介素1β表达降低相关的癌症的方法
EA044002B1 (ru) 1,2,4-оксадиазольные соединения в качестве ингибиторов сигнальных путей cd47

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221102

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221102

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20231031

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20231031

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20231102

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240306

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240612

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241003

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241217

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250116

R150 Certificate of patent or registration of utility model

Ref document number: 7623279

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150